DOCSLIB.ORG

Angiotensin II-Receptor Blockers: Will They Replace Angiotensin-Converting Enzyme Inhibitors in the Treatment of Hypertension?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Angiotensin II-Receptor Blockers: Will They Replace Angiotensin-Converting Enzyme Inhibitors in the Treatment of Hypertension? Journal of Human Hypertension (2000) 14, Suppl 1, S87–S90 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh Angiotensin II-receptor blockers: will they replace angiotensin-converting enzyme inhibitors in the treatment of hypertension? NM Kaplan University of Texas, Southwestern Medical Center, Dallas, TX, USA In the past few years, angiotensin II-receptor blockers outcome data are available, they should continue to be have become available and are being heavily marketed used primarily in patients who should receive an ACEI and increasingly used. In various ways they differ from but cannot tolerate the drug because of cough. Journal angiotensin-converting enzyme inhibitors (ACEIs). Until of Human Hypertension (2000) 14, Suppl 1, S87–S90. Keywords: angiotensin II; angiotensin-converting enzyme inhibitors; angiotensin II-receptor blockers Introduction tensive drug. The newness of this class has contrib- uted further to their use by those practitioners who Over the past 2 years, the greatest relative growth in are attracted to the latest fashions in medicine, sales of hypertensive drugs in the US has been while at the same time it has held back their use by among the angiotensin II-receptor blockers (ARBs) those more conservative practitioners who change (Figure 1). At the same time, sales of angiotensin- their prescribing habits only slowly, if at all. Over- converting enzyme inhibitors (ACEIs) have con- all, the marketing of this new class has overcome a tinued to increase, although they remain below both good deal of the hesitation since many more pre- diuretics and calcium antagonists in total usage. scriptions have been written than would be Similar figures have been noted in most other coun- expected if they were used only in the situation re- tries with the exception of Japan where ARBs have commended by both the US Joint National Commit- not yet been approved, most likely because none tee (JNC-6)1 and the World Health Organization/ have been developed by Japanese pharmaceutical International Society of Hypertension (WHO/ISH),2 companies. namely in those patients who cannot tolerate an The rapid growth of ARBs have occurred in large ACEI because of cough. part because of the intensive and effective marketing Part of the rapid growth in the ARB family reflects of the most recently introduced class of antihyper- the availability of a drug that has few adverse effects beyond that noted with placebo.3 Every practitioner has patients who have experienced side effects from virtually every class of antihypertensive drugs, so there is a natural inclination to use a drug that is not only new and therefore untried but also that promises better acceptability by those who have ‘been through the lot’. Differences between ARBs and ACEIs The recommendations of both the 1997 JNC-6 and the 1999 WHO/ISH guidelines that ARBs are specifically indicated only in patients who should be given an ACEI but who cannot tolerate that choice because of a cough, may give rise to the per- ception that the two classes are essentially the same—except for the absence of cough with the ARBs. Increasingly convincing evidence shows that Figure 1 Sales of major classes of antihypertensive drugs in the they are different in a number of ways, differences US from 1986 to 1998. which may end up favouring one over the other or which may recommend they be used together for Correspondence: Dr NM Kaplan, University of Texas, Southwest- effects additive to what one alone can provide. ern Medical Center, Dallas, TX, USA Before further considerations of the clinical use of Angiotensin II-receptor blockers NM Kaplan S88 these drugs, a brief review of the fundamentals of Table 1 AT1 and AT2 receptor-mediated activities their mechanisms of action will be provided. ACEIs act to inhibit the activity of the ACE enzyme, which AT1 Receptor AT2 Receptor converts the impotent angiotensin I to the potent angiotensin II, while at the same time it breaks down Vasoconstriction Stimulation of apoptosis 4 Simulation of aldosterone Antiproliferative bradykinin to inactive fragments (Figure 2). The tra- synthesis and release ditional pathway for angiotensin synthesis, from Renal tubular sodium Embryonic differentiation and angiotensinogen to AI to AII, can be circumvented reabsorption development by non-ACE alternative pathways including that Cardiac growth Endothelial cell growth Vascular smooth muscle Vasodilation involving the enzyme chymase, which has been proliferation found in high concentrations in heart muscle. Thus Augmentation of peripheral AII may be found in blood and tissues even with noradrenergic activity effective ACE inhibition. Augmentation of central The most widely recognised functions of angio- sympathetic nervous system activity tensin II are mediated through its binding to the AT1 Stimulation of vasopressin receptor on cell membranes. The currently available release ARBs, shown as AT1RA in Figure 2, block the bind- Decreased renal blood flow ing of AII upon this receptor. As a consequence of Renal renin inhibition this blockade, circulating levels of AII, with no place to be bound, increase.5 These increased levels of cir- culating AII are then free to bind onto other AII of ACEI therapy: a dry, non-productive, hacking receptors, of which the AT2 receptor is the next best cough seen in up to 15% of patients overall. As characterised. Although most of the activities bothersome as this cough may be, preventing the mediated by the AT2 receptor appear to be beneficial continued intake of an ACEI by perhaps 5% of so that their stimulation could be useful, there may patients, the increased levels of bradykinin may also be other long-term adverse effects mediated through be beneficial in enhancing the overall effectiveness this or other AT receptors which have not yet been and benefits of ACEI therapy. recognised (Table 1). Research into the effects of Experimental evidence suggests a protective effect stimulation of the AT2 and other angiotensin recep- of bradykinin6 and a lesser effectiveness of ARBs tors is ongoing. than ACEIs in lowering blood pressure and revers- Therefore ARBs may be pharmacologically ing left ventricular hypertrophy.7 Much more superior to ACEIs by blocking the adverse effects of impressive are the data published by Gainer et al8 in whatever AII that is synthesized through non-ACE humans (Figure 3). In their study, 20 normotensive pathways. On the other hand, ARBs may be pharma- subjects and seven hypertensive patients were stud- cologically inferior to ACEIs both because they do ied while on a very low sodium diet that raised the not lead to increased levels of bradykinin and level of their renin-angiotensin activity. They because they could lead to detrimental actions received, randomly, four drugs: a placebo, an ACEI mediated through other AII receptors. (captopril, 25 mg), the ACEI with a specific bradyki- nin-receptor antagonist (icatibant acetate) and an The potential benefits of increased bradykinin The increased levels of bradykinin that are provided when ACEIs inhibit its breakdown are almost cer- tainly responsible for the most common side effect Figure 3 The acute changes in mean arterial pressure in seven hypertensive subjects given placebo, the ARB losartan, the ACE inhibitor captopril with the bradykinin inhibitor icatibant, and Figure 2 The renin-angiotensin system with the site of blockade the ACE inhibitor alone. (Reproduced with permission from 8 of the AT1-receptor (AT1RA). Gainer et al, 1998 ). Journal of Human Hypertension Angiotensin II-receptor blockers NM Kaplan S89 ARB (losartan, 75 mg). As seen in Figure 3, captopril Side effects with ARBs alone lowered the blood pressure the most whereas captopril plus bradykinin-receptor antagonist was Lastly, ARBs are not entirely benign and free of side less effective and equal to the effect of the ARB effects despite the data from initial observations. alone. These data are in keeping with an extra effect With larger experience, angioneurotic oedema was of the ACEI that is provided by the rise in brady- attributed to the ARB losartan in 13 cases through 20 kinin that accompanies its action. Without the extra the Netherlands Pharmacovigilance Foundation. boost from bradykinin, the ACEI is no more effective One case of dysgeusia has also been attributed to 21 than the ARB. losartan. Only time will tell whether more side These data are short-term and in subjects with an effects will surface with larger exposure to these activated renin-angiotensin system. They do, none- agents. theless, serve as support for an additional benefit from the rise in bradykinin that accompanies the Conclusion action of an ACEI. Long-term randomised controlled trials comparing one or another ACEI versus one or As for now, the recommendation of both the US another ARB in patients with hypertension, renal JNC-6 and the WHOISH seem appropriate: use ARBs damage or heart failure are in progress. When they only in those who need an ACEI but who develop a are published, we will know whether one or another cough. In the near future, much more evidence will is better or whether they should be used together. be forthcoming to either expand or restrict the use of Until such data becomes available, the current re- this interesting new class of antihypertensive drugs. commendation—use an ARB only if cough pre- cludes use of an ACEI—seems appropriate. References The long experience with ACEIs 1 Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. This recommendation is made not on the expec- The Sixth Report of the Joint National Committee on tation that ACEIs will turn out to be better than Prevention, Detection, Evaluation, and Treatment of ARBs but rather on the certainty that ACEIs provide High Blood Pressure (JNC-VI). Arch Intern Med 1997; numerous benefits based upon the immense 20-year 157: 2413–2446.
Load more

Recommended publications
  • Renoprotective Effect of the Addition of Losartan to Ongoing Treatment with an Angiotensin Converting Enzyme Inhibitor in Type-2 Diabetic Patients with Nephropathy
    929 Hypertens Res Vol.30 (2007) No.10 p.929-935 Original Article Renoprotective Effect of the Addition of Losartan to Ongoing Treatment with an Angiotensin Converting Enzyme Inhibitor in Type-2 Diabetic Patients with Nephropathy Hirohiko ABE1), Shinya MINATOGUCHI1), Hiroshige OHASHI1), Ichijiro MURATA1), Taro MINAGAWA1), Toshio OKUMA1), Hitomi YOKOYAMA1), Hisato TAKATSU1), Tadatake TAKAYA1), Toshihiko NAGANO1), Yukio OSUMI1), Masao KAKAMI1), Tatsuo TSUKAMOTO1), Tsutomu TANAKA1), Kunihiko HIEI1), and Hisayoshi FUJIWARA1) Angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) are fre- quently used for the treatment for glomerulonephritis and diabetic nephropathy because of their albumin- uria- or proteinuria-reducing effects. To many patients who are nonresponsive to monotherapy with these agents, combination therapy appears to be a good treatment option. In the present study, we examined the effects of the addition of an ARB (losartan) followed by titration upon addition and at 3 and 6 months (n=14) and the addition of an ACE-I followed by titration upon addition and at 3 and 6 months (n=20) to the drug regimen treatment protocol in type 2 diabetic patients with nephropathy for whom more than 3-month administration of an ACE-I or the combination of an ACE-I plus a conventional antihypertensive was inef- fective to achieve a blood pressure (BP) of 130/80 mmHg and to reduce urinary albumin to <30 mg/day. Dur- ing the 12-month treatment, addition of losartan or addition of an ACE-I to the treatment protocol reduced systolic blood pressure (SBP) by 10% and 12%, diastolic blood pressure (DBP) by 7% and 4%, and urinary albumin excretion by 38% and 20% of the baseline value, respectively.
    [Show full text]
  • Cough Induced by Enalapril but Not by Captopril
    Eur Respir J 1989, 2, 289-291 CASE REPORT Cough induced by enalapril but not by captopril H. Puolijoki*, M. Nieminen*, E. Moilanen**, L. Siitonen*, A. Lahdensuo*, P. Reinikainen*, H. Vapaatalo** Cough iruluced by enalapril but 1101 by capropril. H. Puolijoki, M Nieminen, •Tampere University Central Hospital. E. Moilanen, L. Siironen, A. Lahdensuo, P. Reinikainen, If. VapaaJalo. •• Dept of Biomedical Sciences, University of ABSTRACT: We report a 68 yr old woman with hypertension wbo Tampcre. Finland. developed a dry cough on enalaprll but not on captopril therapy. Pul­ monary function te!its, methacholine in halation challenges, total blood Correspondence: H. Puolijoki, Dept of Pulmonary Diseases, Turlcu University Central Hospital, SF- eoslnophiJ counts, and changes In plasma concentrations or prostaglandin 207 40 Preitila, Finland. E2 and tllromboxane 81 did not explain the difference in the adverse reaction between tbese two angiotensin converting enzyme inhibitors. Keywords: ACE inhibitors; captopril; cough; Eur Respir J., 1989, 2, 289- 291. enalapril. Received: March, 1988; accepted after revision August 9, 1988. Angiotensin converting enzyme (ACE) inhibiLors like Case History capropril and ena1april are usually well tolerated. How­ ever, in some patientS they may cause cough as an A 68 yr old non-smoking woman with diabetes, adverse reaction [1]. We report a female patiem who hypertension and compensated heart failure, but with developed a cough on enalapril but not on captopril no respiratory disease or abnormalities on chest X-ray, therapy. We evaluated her lung function, bronchial re­ developed a dry cough but no dyspnoea or posrnasal activity to methacholine, LolaJ blood eosinophi l count as drip during Lreatmem with ena1april (Renitcc®, MSD, E 20 mg·day·1) for hypertension.
    [Show full text]
  • Ace Inhibitors (Angiotensin-Converting Enzyme)
    Medication Instructions Ace Inhibitors (Angiotensin-Converting Enzyme) Generic Brand Benazepril Lotensin Captopril Capoten Enalapril Vasotec Fosinopril Monopril Lisinopril Prinivil, Zestril Do not Moexipril Univasc Quinapril Accupril stop taking Ramipril Altace this medicine Trandolapril Mavik About this Medicine unless told ACE inhibitors are used to treat both high blood pressure (hypertension) and heart failure (HF). They block an enzyme that causes blood vessels to constrict. This to do so allows the blood vessels to relax and dilate. Untreated, high blood pressure can damage to your heart, kidneys and may lead to stroke or heart failure. In HF, using by your an ACE inhibitor can: • Protect your heart from further injury doctor. • Improve your health • Reduce your symptoms • Can prevent heart failure. Generic forms of ACE Inhibitors (benazepril, captopril, enalapril, fosinopril, and lisinopril) may be purchased at a lower price. There are no “generics” for Accupril, Altace Mavik, and of Univasc. Thus their prices are higher. Ask your doctor if one of the generic ACE Inhibitors would work for you. How to Take Use this drug as directed by your doctor. It is best to take these drugs, especially captopril, on an empty stomach one hour before or two hours after meals (unless otherwise instructed by your doctor). Side Effects Along with needed effects, a drug may cause some unwanted effects. Many people will not have any side effects. Most of these side effects are mild and short-lived. Check with your doctor if any of the following side effects occur: • Fever and chills • Hoarseness • Swelling of face, mouth, hands or feet or any trouble in swallowing or breathing • Dizziness or lightheadedness (often a problem with the first dose) Report these side effects if they persist: • Cough – dry or continuing • Loss of taste, diarrhea, nausea, headache or unusual fatigue • Fast or irregular heartbeat, dizziness, lightheadedness • Skin rash Special Guidelines • Sodium in the diet may cause you to retain fluid and increase your blood pressure.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • CONSUMER INFORMATION Increased Risk of Getting an Allergic Reaction That Is Passed Down Through Families
    IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION increased risk of getting an allergic reaction that is passed down through families. This can be triggered by different PrSandoz Trandolapril factors, such as surgery, flu, or dental procedures. Trandolapril Capsules You have diabetes or kidney disease and are already taking a blood pressure-lowering medicine that contains aliskiren Read this carefully before you start taking Sandoz (such as Rasilez®) or an angiotensin II receptor blocker Trandolapril and each time you get a refill. This leaflet is a (ARB). You can recognize ARBs because the name of their summary and will not tell you everything about Sandoz medicinal ingredient ends in “-sartan”. Trandolapril. Talk to your doctor, nurse, or pharmacist Are pregnant or intend to become pregnant. Taking Sandoz about your medical condition and treatment and ask if Trandolapril during pregnancy can cause injury and even there is any new information about Sandoz Trandolapril. death to your baby. Are breastfeeding. Sandoz Trandolapril passes into breast milk. ABOUT THIS MEDICATION Have one of the following rare hereditary diseases: o Galactose intolerance What the medication is used for: o Lapp lactase deficiency Sandoz Trandolapril is used to treat; o Glucose-galactose malabsorption High blood pressure. Because lactose is a non-medicinal ingredient in Sandoz Patients after a heart attack. Trandolapril. Managing your lifestyle What the medicinal ingredient is: The “lifestyle” part of your treatment is as important as Trandolapril your medication. In collaboration with your doctor, you can help reduce the risk of high blood pressure complications to What the non-medicinal ingredients are: maintain the lifestyle you are accustomed to.
    [Show full text]
  • Angiotensin-Converting Enzyme (ACE) Inhibitors
    Angiotensin-Converting Enzyme (ACE) Inhibitors Summary Blood pressure reduction is similar for the ACE inhibitors class, with no clinically meaningful differences between agents. Side effects are infrequent with ACE inhibitors, and are usually mild in severity; the most commonly occurring include cough and hypotension. Captopril and lisinopril do not require hepatic conversion to active metabolites and may be preferred in patients with severe hepatic impairment. Captopril differs from other oral ACE inhibitors in its rapid onset and shorter duration of action, which requires it to be given 2-3 times per day; enalaprilat, an injectable ACE inhibitor also has a rapid onset and shorter duration of action. Pharmacology Angiotensin Converting Enzyme Inhibitors (ACE inhibitors) block the conversion of angiotensin I to angiotensin II through competitive inhibition of the angiotensin converting enzyme. Angiotensin is formed via the renin-angiotensin-aldosterone system (RAAS), an enzymatic cascade that leads to the proteolytic cleavage of angiotensin I by ACEs to angiotensin II. RAAS impacts cardiovascular, renal and adrenal functions via the regulation of systemic blood pressure and electrolyte and fluid balance. Reduction in plasma levels of angiotensin II, a potent vasoconstrictor and negative feedback mediator for renin activity, by ACE inhibitors leads to increased plasma renin activity and decreased blood pressure, vasopressin secretion, sympathetic activation and cell growth. Decreases in plasma angiotensin II levels also results in a reduction in aldosterone secretion, with a subsequent decrease in sodium and water retention.[51035][51036][50907][51037][24005] ACE is found in both the plasma and tissue, but the concentration appears to be greater in tissue (primarily vascular endothelial cells, but also present in other organs including the heart).
    [Show full text]
  • Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin
    DOI: 10.7860/JCDR/2018/31983.11754 Original Article Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Pharmacology Section Receptor Blockers-A Pilot Study S BHUVANESHWARI1, PRAKASH VEL SANKHYA SAROJ2, D VIJAYA3, M SABARI SOWMYA4, R SENTHIL KUMAR5 ABSTRACT Results: Among all, 48% (24 out of 50) of the study population Introduction: Hyponatremia, serum sodium <135 mmol/L, can administered with ACEI and ARB developed hyponatremia. result in neurological manifestation in acute cases, may lead Predisposition to develop hyponatremia was high in males to seizures and coma. Angiotensin Converting Enzyme Inhibitor compared to females. Incidence of hyponatremia was 62.5% (10 (ACEI) and Angiotensin II Receptor Blockers (ARB) are drugs out of 16) in the age group of 56-75 years. Though, incidence of that have been commonly prescribed for the treatment of hyponatremia was 54.5% (18 out of 33) in ACEI group compared hypertension and cardiac diseases. It has become important to 35.2% (6 out of 17) in ARB group, but it was not statistically to evaluate and investigate the incidence of hyponatremia on significant. The study also revealed that metosartan had a higher consumption of these drugs. association with hyponatremia compared to other drugs. Aim: To determine the susceptibility of patients on ACEI and Conclusion: Hyponatremia was induced in nearly 50% of ARB to hyponatremia and to ascertain the drug producing patients taking ACEI and ARB. The incidence of hyponatremia notable hyponatremia among ACEI and ARB. among patients on these two drugs did not show statistical variation. Metosartan showed a higher incidence of Materials and Methods: The study was conducted in a tertiary hyponatremia compared to enalapril, ramipril, captopril, care hospital.
    [Show full text]
  • M03-599 Clinical Study Report R&D/06/211
    ABT-897 M03-599 Clinical Study Report R&D/06/211 2.0 Synopsis Abbott Laboratories Individual Study Table Referring (For National Authority to Part of Dossier: Use Only) Name of Study Drug: Volume: Tarka® Name of Active Ingredient: Page: trandolapril and verapamil SR Title of Study: A Phase 4, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects with Diabetic Nephropathy Investigator: Multicenter study. Coordinating investigator is Robert Toto, MD Study Sites: A total of 66 sites in the United States enrolled study subjects. Publications: None Studied Period (Years): Phase of Development: 4 First Subject First Visit: 07 Jan 2004 Last Subject Last Visit: 24 Jan 2006 Objectives: The primary objective of this study was to determine if trandolapril/verapamil SR (Tarka®) was superior to amlodipine/benazepril (Lotrel®) in the reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and diabetic nephropathy. Albuminuria was to be determined as the urine albumin:creatinine ratio (UACR). The secondary objectives of this study were: 1. To compare the effects of Tarka and Lotrel on changes in blood pressure (BP) and BP control, proteinuria, estimated glomerular filtration rate (GFR). 2. To compare antihypertensive drug use in each treatment group by drug, dose, and class. 3. To compare the safety profile of Tarka and Lotrel by evaluating lipid parameters, glycemic control, quality of life using the 36-Item Short Form Health Survey (SF-36), and adverse events. 4. From a substudy, to explore the effects of Tarka and Lotrel on serum high-sensitivity C-reactive protein (hsCRP), urinary malondialdehyde (MDA) and carbonylated proteins as oxidative stress markers, urinary monocyte chemotactic protein-1 (MCP-1) as an inflammatory marker, transforming growth factor-β (TGF- β) as a profibrotic marker, proteinuria selectivity index, and ambulatory blood pressure parameters.
    [Show full text]
  • 5 Mg Film-Coated Tablets [Nationally Completed Name] 10 Mg Film-Coated Tablets [Nationally Completed Name] 20 Mg Film-Coated Tablets
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT [nationally completed name] 5 mg film-coated tablets [nationally completed name] 10 mg film-coated tablets [nationally completed name] 20 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains 5/10/20 mg Benazepril hydrochloride. For the full list of excipients see section 6.1 3. PHARMACEUTICAL FORM Film-coated tablet [nationally completed name] 5 mg film-coated tablets: Oval (4 x 8 mm), light yellow film-coated tablets with score on both sides. [nationally completed name] 10 mg film-coated tablets: Oval (11 x 5.5 mm) yellow film-coated tablets with score on both sides. [nationally completed name] 20 mg film-coated tablets: Oval (11 x 5.5 mm) light red film-coated tablet with score on both sides. The tablet can be divided into equal doses. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Essential hypertension, congestive heart failure - in addition to diuretics and especially to digitalis glycosides in cases of severe congestive heart failure 4.2 Posology and method of administration Posology Paediatric population [nationally completed name] is not recommended for use in children due to insufficient data on safety and efficacy (see section 4.4). Essential hypertension 10 to 20 mg daily divided in one or two doses. Maximum daily dose is 40 mg. Congestive heart failure Initially 2.5 mg daily. After 2-4 weeks the dosage can be increased to 5 mg daily. Maximum dose is 20 mg daily. Dosage at renal impairment For the treatment of essential hypertension the dose should be reduced if creatinine clearance is below 30 ml/min.
    [Show full text]
  • Switching Ace-Inhibitors
    Switching Ace-inhibitors http://www.ksdl.kamsc.org.au/dtp/switching_ace_inhibitors.html Change to → Enalapril Quinapril Ramipril Change from ↓ (Once daily dosing) (Once daily dosing) (Once daily dosing) Captopril Captopril 12.5mg daily Enalapril 2.5mg1 Quinapril 2.5mg Ramipril 1.25mg Captopril 25mg daily Enalapril 5mg1 Quinapril 5mg Ramipril 1.25-2.5mg Captopril 50mg daily Enalapril 7.5mg1 Quinapril 10mg Ramipril 2.5-5mg Captopril 100mg daily Enalapril 20mg1 Quinapril 20mg Ramipril 5-10mg2 Captopril 150mg daily Enalapril 40mg Quinapril 40mg Ramipril 10mg Fosinopril Fosinopril 5mg daily Enalapril 5mg Quinapril 5mg Ramipril 1.25mg Fosinopril 10mg daily Enalapril 10mg Quinapril 10mg Ramipril 2.5mg Fosinopril 20mg daily Enalapril 20mg Quinapril 20mg Ramipril 5mg Fosinopril 40mg daily Enalapril 40mg Quinapril 40mg Ramipril 10mg Lisinopril Lisinopril 5mg daily Enalapril 5mg Quinapril 5mg Ramipril 1.25mg Lisinopril 10mg daily Enalapril 10mg Quinapril 10mg Ramipril 2.5mg Lisinopril 20mg daily Enalapril 20mg Quinapril 20mg Ramipril 5mg Lisinopril 40mg Enalapril 40mg Quinapril 40mg Ramipril 10mg Perindopril Perindopril 2mg daily Enalapril 5-10mg Quinapril 5-10mg Ramipril 2.5mg Perindopril 4mg daily Enalapril 10mg-20mg Quinapril 10mg-20mg Ramipril 5mg Perindopril 8mg daily Enalapril 20-40mg Quinapril 20-40mg Ramipril 10mg Trandolapril Trandolapril 0.5mg d Enalapril 5mg Quinapril 5mg Ramipril 1.25mg Trandolapril 1mg daily Enalapril 10mg Quinapril 10mg Ramipril 2.5mg Trandolapril 2mg daily Enalapril 20mg Quinapril 20mg Ramipril 5mg Trandolapril 4mg daily Enalapril 40mg Quinapril 40mg Ramipril 10mg There are few studies comparing equivalent doses of ACE-inhibitors, for specific indications. Therefore, the above recommendations are based on clinical experiences and are not specific for any indication.
    [Show full text]
  • The Treatment of Severe Hypertension with Trandolapril, Verapamil, and Hydrochlorothiazide
    Journal of Human Hypertension (1997) 11, 477–481 1997 Stockton Press. All rights reserved 0950-9240/97 $12.00 ORIGINAL ARTICLE The treatment of severe hypertension with trandolapril, verapamil, and hydrochlorothiazide HA Punzi1 and BA Novrit2 for the Trandolapril/Verapamil Multicenter Study Group 1Trinity Hypertension Research Center, Trinity Medical Center, Carrollton, TX; and 2Knoll Pharmaceutical Company, Mt Olive, NJ, USA A multiple drug regimen consisting of trandolapril, vera- than the decrease observed for the TV combination, pamil and hydrochlorothiazide (HCTZ) were sequentially which was significantly (P = 0.001) greater than the added in an open-label evaluation of patients with sev- decrease observed for trandolapril monotherapy. Clini- ere hypertension. Ninety patients (58 white and 32 black cal responder rates were 44.8%, 56% and 77.7% for tran- patients) were titrated on one or more drugs and fol- dolapril monotherapy, trandolapril + verapamil combi- lowed for a 19-week maintenance period. Statistically nation therapy and triple therapy, respectively. Black significant (P = 0.001) mean (± s.d.) decreases in supine and white patients had similar response rates, but black diastolic blood pressure (DBP) were 9.0 (±9.3) mm Hg patients appeared to benefit more from the addition of for trandolapril, 13.9 (±11.0) mm Hg for the trandolapril HCTZ; 20% of black patients achieved a post-treatment + verapamil (TV) combination, and 19.0 (±12.3) mm Hg supine DBP ,90 mm Hg compared to 12.8% of white when hydrochlorothiazide was added to the combi- patients. This study demonstrates that the addition of nation. The decrease in BP observed on TV combination verapamil to trandolapril has an additive effect on BP therapy plus HCTZ was significantly (P = 0.001) greater that is maintained throughout the day.
    [Show full text]
  • Sacubitril and Valsartan
    PATIENT & CAREGIVER EDUCATION Sacubitril and Valsartan This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Entresto Brand Names: Canada Entresto Warning Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away. What is this drug used for? It is used to treat heart failure (weak heart). It is used to lower the risk of death and having to go to the hospital because of heart failure. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have liver disease. Sacubitril and Valsartan 1/6 If you have ever had a very bad or life-threatening reaction called angioedema. Signs may be swelling of the hands, face, lips, eyes, tongue, or throat; trouble breathing; trouble swallowing; unusual hoarseness. If you are taking another drug that has the same drug in it. If you are taking of these drugs: Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, or telmisartan. If you are taking or have recently taken any of these drugs: Benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, or trandolapril. If you are taking a drug that has aliskiren in it and you also have diabetes or kidney problems.
    [Show full text]